Efficacy and safety of corticosteroids for community-Acquired pneumonia: A systematic review and meta-Analysis

Chest

Volumn 149, Issue 1, 2016, Pages 209-219

  Wan, You Dong ^a   Sun, Tong Wen ^a   Liu, Zi Qi ^a   Zhang, Shu Guang ^a   Wang, Le Xin ^b   Kan, Quan Cheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

C reactive protein; Community Acquired pneumonia; Critical care

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; METHYLPREDNISOLONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMPYEMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SUPERINFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; COMMUNITY-ACQUIRED INFECTIONS; PNEUMONIA;

ADRENAL CORTEX HORMONES; ADULT; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; LENGTH OF STAY; PNEUMONIA; TREATMENT OUTCOME;

EID: 84954148193     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-1733     Document Type: Article

References (27)

1. WHO. The top 10 causes of death. World Health Organization website. http://www. who.int/mediacentre/factsheets/fs310/en/index1.html. Accessed June 10, 2015.
2. Wunderink RG, Waterer GW. Clinical practice. Community-Acquired pneumonia. N Engl J Med. 2014;370(6): 543-551.
3. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-Acquired pneumonia patients. Eur Respir J. 2015;45(2): 463-472.
4. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-Acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677-686.
5. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-Acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511-1518.
6. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with communityacquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-2030.
7. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-Acquired pneumonia in adults: a meta-Analysis. Plos One. 2012;7(10):e47926.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ. 2009;339:b2535.
9. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is quality of evidence and why is it important to clinicians? BMJ. 2008;336(7651):995-998.
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. Cochrane Collaboration 2011. Cochrane Collaboration website. www.cochrane-handbook.org. Accessed October 28, 2015.
11. Chou R, Fu R, Carson S, Saha S, Helfand M. Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. J Clin Epidemiol. 2007;60(1):18-28.
12. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-Analysis. J Clin Epidemiol. 2008;61(1):64-75.
13. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjunct role of corticosteroids in the treatment of community-Acquired pneumonia. Egypt J Chest Dis. 2013;62(3): 439-445.
14. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-Acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96.
15. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-Acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-982.
16. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-Acquired pneumonia requiring hospitalization. Lung. 2007;185(5):249-255.
17. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-Acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3): 242-248.
18. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-Acquired pneumonia. A randomized controlled study. Chest. 1993;104(2):389-392.
19. Ugajin M, Yamaki K, Hirasawa N, Kobayashi T, Yagi T. Impact and indication of early systemic corticosteroids for very severe community-Acquired pneumonia. Int J Gen Med. 2013;6: 693-701.
20. Polverino E, Cilloniz C, Dambrava P, et al. Systemic corticosteroids for communityacquired pneumonia: reasons for use and lack of benefit on outcome. Respirology. 2013;18(2):263-271.
21. Chon GR, Lim CM, Koh Y, Hong SB. Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe community-Acquired pneumonia. J Infect Chemother. 2011;17(4):449-455.
22. Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-Acquired pneumonia: a cohort study. J Crit Care. 2011;26(2):193-200.
23. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-Acquired pneumonia. Eur Respir J. 2007;30(5):951-956.
24. Wang HJ, Bennett IJ, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956;98(3):197-215.
25. McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Br Med J. 1972;4(5840): 569-573.
26. Sabry NA, Omar EE-D. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011;2(2): 73-81.
27. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with communityacquired pneumonia: a systematic review and meta-Analysis. Ann Intern Med. 2015;163(7):519-528.